大株紅景天注射液對晚期乳腺癌患者生活質(zhì)量和免疫功能的影響

蘇國新 朱小麗 蘇雅萍 李玲玲 陳赫軍 種寶貴 馬紅芳

[摘要] 目的 觀察大株紅景天注射液聯(lián)合化療藥物對晚期乳腺癌患者生活質(zhì)量和免疫功能的影響。 方法 選取2014年6月～2016年6月衡水市哈勵遜國際和平醫(yī)院行化療藥物治療的分期為Ⅳ期的56例乳腺癌患者，采用隨機(jī)數(shù)字表法分將其為觀察組和對照組，每組各28例。兩組化療方案均選擇紫杉醇聯(lián)合順鉑，同時觀察組在該化療方案基礎(chǔ)上聯(lián)合靜脈滴注大株紅景天注射液。在治療2個周期后，對臨床治療效果進(jìn)行監(jiān)測和評價。觀察兩組細(xì)胞免疫學(xué)相關(guān)的指標(biāo)變化：檢測兩組治療前后CD3+、CD4+、CD4+/CD8+、CD8+、NK值。測量兩組患者的血常規(guī)、肝腎功能及心功能的各項(xiàng)指標(biāo)，記錄治療期間的藥物不良反應(yīng)情況及分級。 結(jié)果 經(jīng)過2個周期的治療后，兩組CD3+、CD4+、CD4+/CD8+及NK細(xì)胞均高于治療前，CD8+低于治療前，差異有統(tǒng)計學(xué)意義（P < 0.05）。觀察組CD3+、CD4+、CD4+/CD8+、NK細(xì)胞在治療后明顯高于對照組，CD8+明顯低于對照組，差異有統(tǒng)計學(xué)意義（P < 0.05）。觀察組在聯(lián)合治療期間心臟毒性、惡心嘔吐的發(fā)生率均明顯低于對照組，差異有統(tǒng)計學(xué)意義（P < 0.05）。觀察組生活質(zhì)量改善情況優(yōu)于對照組，差異有統(tǒng)計學(xué)意義（P < 0.05），但兩組之間的療效比較，差異無統(tǒng)計學(xué)意義（P > 0.05）。結(jié)論 大株紅景天注射液聯(lián)合化療藥物能夠顯著改善晚期乳腺癌患者的細(xì)胞免疫水平，提高其生活質(zhì)量。

[關(guān)鍵詞] 大株紅景天注射液;晚期乳腺癌;免疫功能;生活質(zhì)量

[中圖分類號] R737.9? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1673-7210（2019）07（b）-0133-04

Effects of Sofren Injection on quality of life and immune function in patients with advanced breast cancer

SU Guoxin? ?ZHU Xiaoli? ?SU Yaping? ?LI Lingling? ?CHEN Hejun? ?CHONG Baogui? ?MA Hongfang

Department of Medicine， Hengshui Harrison International Peace Hospital， Hebei Province， Hengshui? ? 053000， China

[Abstract] Objective To observe the effects of Sofren Injection on quality of life and immune function in patients with advanced breast cancer. Methods Form June 2014 to June 2016， 56 cases of breast cancer patients with Ⅳ stage who received chemotherapy treatment in Hengshui Harrison International Peace Hospital were selected and divided into observation group and control group by the random number table method， with 28 cases in each group. Both groups selected Paclitaxel combined with Cisplatin chemotherapy regiments， and the observation group was given Sofren Injection by intravenous drip on the basis of the chemotherapy regiments. After 2 cycles of chemotherapy， the clinical efficacy was monitored and evaluated. The indexes related to cell immunology in the two groups were observed： CD3+， CD4+， CD4+/CD8+， CD8+ and NK values were measured and calculated before and after chemical drug treatment in the two groups. The blood routine， liver and kidney function and cardiac function of the patients were measured， and the adverse drug reactions and grades during the hospitalization were recorded. Results After 2 cycles of treatment， CD3+， CD4+， CD4+/CD8+ and NK cells in the two groups were all higher than those before chemotherapy， and CD8+ was lower than before treatment， with statistically significant differences （P < 0.05）. CD3+， CD4+， CD4+/CD8+ and NK cells in the observation group were significantly higher than those in the control group after treatment， CD8+ was lower than that of the control group， and the difference was statistically significant （P < 0.05）. The incidence of cardiotoxicity， nausea and vomiting in the observation group was significantly lower than that in the control group during the combined treatment， with statistically significant differences （P < 0.05）. The improvement rate of life quality in the observation group was better than that in the control group， and the difference was statistically significant （P < 0.05）. There was no statistically significant difference in efficacy between the two groups （P > 0.05）. Conclusion Large strains of Sofren Injection combined with chemotherapy drugs can significantly improve the cellular immunity and quality of life of patients with advanced breast cancer.